Related Experiment Video
Updated: Mar 11, 2026
Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
Published on: May 2, 2025
STAT3 Inhibition as a Therapeutic Strategy for Chordoma
Anthony C Wang1, John H Owen2, Waleed M Abuzeid3
1Department of Neurological Surgery, University of Washington School of Medicine, Seattle, Washington, United States.
Abstract:
Objective Signal transducer and activator of transcription (STAT) proteins regulate key cellular fate decisions including proliferation and apoptosis. STAT3 overexpression induces tumor growth in multiple neoplasms. STAT3 is constitutively activated in chordoma, a tumor with a high recurrence rate despite maximal surgical and radiation treatment. We hypothesized that a novel small molecule inhibitor of STAT3 (FLLL32) would induce significant cytotoxicity in sacral and clival chordoma cells. Methods Sacral (UCh1) and clival (UM-CHOR-1) chordoma cell lines were grown in culture (the latter derived from primary tumor explants). FLLL32 dosing parameters were optimized using cell viability assays. Antitumor potential of FLLL32 was assessed using clonal proliferation assays. Potential mechanisms underlying observed cytotoxicity were examined using immunofluorescence assays. Results FLLL32 induced significant cytotoxicity in UCh1 and UM-CHOR-1 chordoma cells, essentially eliminating all viable cells, correlating with observed downregulation in activated, phosphorylated STAT3 upon administration of FLLL32. Mechanisms underlying the observed cytotoxicity included increased apoptosis and reduced cellular proliferation through inhibition of mitosis. Conclusion As a monotherapy, FLLL32 induces potent tumor kill in vitro in chordoma cell lines derived from skull base and sacrum. This effect is mediated through inhibition of STAT3 phosphorylation, increased susceptibility to apoptosis, and suppression of cell proliferation.
Insights
The novel STAT3 inhibitor FLLL32 effectively killed chordoma cells by reducing STAT3 phosphorylation. This targeted therapy shows promise for treating aggressive chordoma tumors.
Area of Science:
- Oncology
- Molecular Biology
- Cellular Biology
Background:
- Signal transducer and activator of transcription (STAT) proteins, particularly STAT3, are crucial in regulating cell proliferation and apoptosis.
- Constitutive STAT3 activation is implicated in chordoma, a challenging tumor with high recurrence rates.
- Targeting STAT3 represents a potential therapeutic strategy for chordoma.
Purpose of the Study:
- To investigate the efficacy of a novel small molecule STAT3 inhibitor, FLLL32, against sacral and clival chordoma cells.
- To determine the mechanisms by which FLLL32 exerts its cytotoxic effects in chordoma.
Main Methods:
- Utilized sacral (UCh1) and clival (UM-CHOR-1) chordoma cell lines.
- Optimized FLLL32 dosing using cell viability assays.
- Assessed antitumor potential via clonal proliferation assays and examined mechanisms using immunofluorescence.
Main Results:
- FLLL32 demonstrated significant cytotoxicity, eliminating viable chordoma cells in both cell lines.
- Observed a correlation between FLLL32 administration and downregulation of phosphorylated STAT3.
- Identified increased apoptosis and reduced cellular proliferation (mitotic inhibition) as key mechanisms.
Conclusions:
- FLLL32 as a monotherapy potently kills chordoma cells in vitro.
- The anti-chordoma effect is mediated by inhibiting STAT3 phosphorylation.
- FLLL32 enhances apoptosis susceptibility and suppresses cell proliferation in chordoma.
